Famitinib is a tyrosine kinase inhibitor that targets VEGFR2, PDGFR, and c-Kit, exhibiting dual antitumor effects through antiproliferative activity and inhibition of angiogenesis. It primarily exerts its effects by inhibiting the activity of multiple receptor tyrosine kinases, including c-Kit, VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), FGFR (fibroblast growth factor receptor), Ret, and Flt3.